A detailed history of Creative Planning transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Creative Planning holds 37,525 shares of PCVX stock, worth $3.26 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,525
Previous 27,280 37.55%
Holding current value
$3.26 Million
Previous $2.06 Million 108.06%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$70.52 - $117.12 $722,477 - $1.2 Million
10,245 Added 37.55%
37,525 $4.28 Million
Q2 2024

Aug 15, 2024

BUY
$60.06 - $78.77 $639,158 - $838,270
10,642 Added 63.96%
27,280 $2.06 Million
Q1 2024

May 10, 2024

BUY
$59.79 - $81.05 $280,295 - $379,962
4,688 Added 39.23%
16,638 $1.14 Million
Q4 2023

Feb 14, 2024

BUY
$45.35 - $63.41 $130,381 - $182,303
2,875 Added 31.68%
11,950 $750,000
Q3 2023

Nov 16, 2023

BUY
$46.0 - $53.1 $121,164 - $139,865
2,634 Added 40.89%
9,075 $462,000
Q2 2023

Jul 21, 2023

BUY
$34.66 - $54.07 $223,245 - $348,264
6,441 New
6,441 $321,000
Q4 2022

Feb 10, 2023

BUY
$20.58 - $47.95 $87,856 - $204,698
4,269 New
4,269 $204,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.15B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.